| Basics |
Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable & inhalation products. Its products are used in hospitals or urgent care clinical settings.
|
| IPO Date: |
June 25, 2014 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$1.22B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.40 | 1.67%
|
| Avg Daily Range (30 D): |
$0.38 | 1.52%
|
| Avg Daily Range (90 D): |
$0.47 | 1.77%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.25M |
| Avg Daily Volume (30 D): |
.4M |
| Avg Daily Volume (90 D): |
.47M |
| Trade Size |
| Avg Trade Size (Sh.): |
67 |
| Avg Trade Size (Sh.) (30 D): |
43 |
| Avg Trade Size (Sh.) (90 D): |
45 |
| Institutional Trades |
| Total Inst.Trades: |
2,281 |
| Avg Inst. Trade: |
$1.79M |
| Avg Inst. Trade (30 D): |
$1.85M |
| Avg Inst. Trade (90 D): |
$1.96M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.09M |
| Avg Closing Trade (30 D): |
$2.1M |
| Avg Closing Trade (90 D): |
$2.45M |
| Avg Closing Volume: |
68.37K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$.53
|
$.83
|
|
Diluted EPS
|
|
$.51
|
$.78
|
|
Revenue
|
$
|
$ 170.53M
|
$ 191.21M
|
|
Gross Profit
|
$
|
$ 85.25M
|
$ 101.94M
|
|
Net Income / Loss
|
$
|
$ 25.29M
|
$ 40.43M
|
|
Operating Income / Loss
|
$
|
$ 37.29M
|
$ 57.05M
|
|
Cost of Revenue
|
$
|
$ 85.28M
|
$ 89.27M
|
|
Net Cash Flow
|
$
|
$ 31.17M
|
$ 2.5M
|
|
PE Ratio
|
|
|
|
|
|
|
